A Study of WVT078 in Patients With Multiple Myeloma (MM)

Status Active, not recruiting

Clinical Trial Summary

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

Clinical Trial Description

This first-in-human trial with WVT078 is a dose escalation study whose primary purpose is to characterize the safety, tolerability, and determine recommended dose regimen(s) of WVT078 alone and in combination with WHG626 in subjects with MM who have received two or more standard of care lines of therapy including an IMID, a proteasome inhibitor, and an anti-CD38 agent (if available) and are relapsed and/or refractory to or intolerant of each regimen. In addition, this study will assess preliminary anti-MM response of and characterize the pharmacokinetics and immunogenicity of WVT078 alone and in combination with WHG626. The results of this study will inform the future development of WVT078 alone and in combination with WHG626 as a treatment for relapsed and/or refractory MM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04123418
Study type	Interventional
Source	Novartis
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 5, 2019
Completion date	December 2, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02265731` - Study Evaluating Venetoclax in Subjects With Hematological Malignancies	Phase 1/Phase 2
Recruiting	`NCT05442580` - CART-38 in Adult AML and MM Patients	Phase 1
Terminated	`NCT04178902` - A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma	Phase 1
Completed	`NCT02920697` - Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma	Phase 1
Recruiting	`NCT05908409` - A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT04702425` - VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)	Phase 1
Completed	`NCT00710528` - Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies	Phase 1
Completed	`NCT04721002` - Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
Active, not recruiting	`NCT02240537` - Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer	Phase 1
Active, not recruiting	`NCT02203643` - Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.	Phase 2
Completed	`NCT02211014` - An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma	Phase 1
Recruiting	`NCT04649073` - Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma	Phase 1/Phase 2
Recruiting	`NCT03018405` - A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications	Phase 1/Phase 2
Terminated	`NCT01663766` - Phase I Study of Milatuzumab for Graft Versus Host Disease	Phase 1
Active, not recruiting	`NCT01919086` - Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma	Phase 2
Withdrawn	`NCT05513612` - Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies	Phase 1
Completed	`NCT01413568` - Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT00889798` - Tumor Registry of Lymphatic Neoplasia